RxDoctor Payments Data

Brittany Tav, MD

Family Medicine · Metairie, LANPI 1871970988

Payments from drug & device makers

$883in general payments, 2019–2025

Across 19 payments — averaging $46.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$163
  • Pfizer$120
  • Edwards Lifesciences$113
  • Vifor Pharma, Inc.$108
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$103
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • plus $175 from 8 others

What the payments were for

  • Food & beverage$883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$883 in reported general payments places this provider in the 50th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$26,428
Medicare patients
138
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$54,749
OzempicSemaglutide14$26,805
JardianceEmpagliflozin26$22,237
EliquisApixaban16$18,543
TrulicityDulaglutide11$18,494
MyrbetriqMirabegron18$14,232
Spiriva RespimatTiotropium Bromide12$6,367
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$3,130
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$1,976
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen69$1,865
Lidocaine13$1,820
Gabapentin112$1,523
Atorvastatin Calcium174$1,346
Albuterol Sulfate HfaAlbuterol Sulfate39$1,232
Duloxetine Hcl51$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$21$28,60438 claims
Novo NordiskOzempic$163$26,80514 claims
PfizerEliquis$120$18,54316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →